EMA Launches Review of Clot Risk With AstraZeneca COVID Vaccine
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is investigating cases of thromboembolic events related to AstraZeneca's COVID-19 vaccine, but says the benefits currently still outweigh risks.
from Google Alert - Business https://ift.tt/2OkU9bY
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is investigating cases of thromboembolic events related to AstraZeneca's COVID-19 vaccine, but says the benefits currently still outweigh risks. https://ift.tt/eA8V8J
from Google Alert - Business https://ift.tt/2OkU9bY
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is investigating cases of thromboembolic events related to AstraZeneca's COVID-19 vaccine, but says the benefits currently still outweigh risks. https://ift.tt/eA8V8J
Comments
Post a Comment